Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse

Clin Infect Dis. 2015 Jan 1;60(1):96-9. doi: 10.1093/cid/ciu742. Epub 2014 Sep 23.

Abstract

Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.

Keywords: fecal shedding; hepatitis E virus; relapse; ribavirin therapy.

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Feces / virology*
  • Female
  • Hepatitis E / drug therapy*
  • Hepatitis E / virology*
  • Hepatitis E virus / isolation & purification*
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation
  • Recurrence
  • Ribavirin / therapeutic use*
  • Treatment Outcome
  • Virus Shedding*

Substances

  • Antiviral Agents
  • Ribavirin